Creo Medical Targets 50-60% Revenue Growth Amid Cost Cuts

Creo Medical, a London-listed firm specializing in minimally invasive surgical endoscopy, has reported first-half 2026 revenue of £3.2m, representing a 45% year-on-year increase. The company simultaneously reduced its underlying operating loss by more than 25% to £4.9m, driven by a 20% reduction in underlying operating costs during the previous period. This financial trajectory indicates a shift from pure research and development toward active commercialization, with management projecting full-year revenue growth between 50% and 60%.

The firm’s Advanced Energy technology enables physicians to dissect tissue through endoscopic devices, a capability increasingly adopted in clinical settings for treating pre-cancerous and cancerous conditions. According to GN stocks/shares-surge, the company’s operational progress suggests the investment thesis is entering a critical phase where sales acceleration is outpacing the cost base, a key metric for investors monitoring speculative medical device equities with market capitalizations below £100m.

Operational Leverage Drives Margin Improvement

Management has implemented structural cost efficiencies, including the outsourcing of manufacturing activities to streamline operations. This strategic shift is expected to reduce the underlying operating cost base by approximately 15% compared to 2025 levels. The combination of rapid revenue expansion and declining fixed costs creates significant operating leverage, moving the business closer to profitability despite current loss-making status.

In full-year 2025, revenue grew 50% to £6m as clinical adoption rates rose. The underlying operating loss in the first half of 2026 improved significantly, reflecting the tangible impact of the cost-cutting measures. The company expects this trend to continue, with the strong order book providing visibility into future revenue streams and supporting the projected growth targets for the remainder of the fiscal year.

Kamaptive Program Expands Market Reach

A key catalyst for future growth is the Kamaptive program, which integrates Creo’s Advanced Energy technology into third-party medical systems, including robotic-assisted surgical platforms. The company has secured an agreement for initial integration with a major global medical technology partner. This licensing model allows Creo to expand its technology’s presence in a substantially larger number of procedures without the capital expense of building proprietary distribution infrastructure.

Expansion into new geographic markets, particularly Latin America, further supports the revenue outlook. By leveraging partner distribution channels, Creo can scale its addressable market more rapidly than through direct sales alone. This strategic approach aims to maximize revenue per customer while maintaining a lean cost structure, addressing the primary concerns of investors regarding the company’s path to sustainable profitability.

Cash Position and Funding Risks

Despite operational improvements, Creo Medical remains a high-risk investment with a flat share price performance over the past year. The company reported cash reserves of £7.4m as of the end of June, which must cover ongoing operations and development costs. Potential future funding requirements could dilute existing shareholders or weigh on sentiment if clinical adoption proceeds slower than anticipated.

Investors remain cautious, waiting for definitive proof that the commercialization phase will generate sufficient cash flow to eliminate reliance on external capital. The stock’s speculative nature is underscored by its classification as a penny stock, with a share price below £1. Success hinges on achieving the targeted 50-60% revenue growth and demonstrating consistent adoption rates in the coming year to validate the business model.